Encephalomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Encephalomyelitis pipeline market research report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.
Key Targets in the Encephalomyelitis Pipeline Market
The key targets in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter, Corticotropin Releasing Factor Receptor 2, DNA Polymerase, Interleukin 10, NACHT LRR And PYD Domains Containing Protein 3, Neurotrophin 3, Nuclear Factor Erythroid 2 Related Factor 2. Sodium Dependent Dopamine Transporter has the highest number of pipeline products.
Encephalomyelitis Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Encephalomyelitis Pipeline Market
The key MoA in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter Inhibitor, Corticotropin Releasing Factor Receptor 2 Agonist, DNA Polymerase Inhibitor, Interleukin 10 Activator, Neurotrophin 3 Activator, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor. Sodium Dependent Dopamine Transporter Inhibitor has the highest number of pipeline products.
Encephalomyelitis Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Encephalomyelitis Pipeline Market
The key RoA in the encephalomyelitis pipeline market are oral, intravenous, intraperitoneal, intravitreal, nasal, and subcutaneous. Oral has the highest number of pipeline market.
Encephalomyelitis Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Encephalomyelitis Pipeline Market
The key molecule types in the encephalomyelitis pipeline market are small molecule, gene-modified cell therapy, oligonucleotide, peptide, protein, and synthetic peptide. Small molecule has the highest number of pipeline products.
Encephalomyelitis Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Encephalomyelitis Pipeline Market
The key companies in the encephalomyelitis pipeline market are AIM ImmunoTech Inc, Biovista Inc, Cortene Inc, F. Hoffmann-La Roche Ltd, K-Pax Pharmaceuticals Inc, NLS Pharmaceutics AG, Orion BioScience Inc, Paxmedica Inc, Telesphore Pharma, Trethera Corp, and Virios Therapeutics Inc.
Market report overview
Key targets | Sodium Dependent Dopamine Transporter, Corticotropin Releasing Factor Receptor 2, DNA Polymerase, Interleukin 10, NACHT LRR And PYD Domains Containing Protein 3, Neurotrophin 3, and Nuclear Factor Erythroid 2 Related Factor 2 |
Key MoA | Sodium Dependent Dopamine Transporter Inhibitor, Corticotropin Releasing Factor Receptor 2 Agonist, DNA Polymerase Inhibitor, Interleukin 10 Activator, Neurotrophin 3 Activator, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor |
Key RoA | Oral, Intravenous, Intraperitoneal, Intravitreal, Nasal, and Subcutaneous |
Key molecule types | Small Molecule, Gene-Modified Cell Therapy, Oligonucleotide, Peptide, Protein, and Synthetic Peptide |
Key companies | AIM ImmunoTech Inc, Biovista Inc, Cortene Inc, F. Hoffmann-La Roche Ltd, K-Pax Pharmaceuticals Inc, NLS Pharmaceutics AG, Orion BioScience Inc, Paxmedica Inc, Telesphore Pharma, Trethera Corp, and Virios Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Biovista Inc
Cortene Inc
F. Hoffmann-La Roche Ltd
K-Pax Pharmaceuticals Inc
NLS Pharmaceutics AG
Orion BioScience Inc
Paxmedica Inc
Telesphore Pharma
Trethera Corp
Virios Therapeutics, Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the encephalomyelitis pipeline market?
The key targets in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter, Corticotropin Releasing Factor Receptor 2, DNA Polymerase, Interleukin 10, NACHT LRR And PYD Domains Containing Protein 3, Neurotrophin 3, Nuclear Factor Erythroid 2 Related Factor 2.
-
What are the key MoA in the encephalomyelitis pipeline market?
The key MoA in the encephalomyelitis pipeline market are Sodium Dependent Dopamine Transporter Inhibitor, Corticotropin Releasing Factor Receptor 2 Agonist, DNA Polymerase Inhibitor, Interleukin 10 Activator, Neurotrophin 3 Activator, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor.
-
What are the key RoA in the encephalomyelitis pipeline market?
The key RoA in the encephalomyelitis pipeline market are oral, intravenous, intraperitoneal, intravitreal, nasal, and subcutaneous.
-
What are the key molecule types in the encephalomyelitis pipeline market?
The key molecule types in the encephalomyelitis pipeline market are small molecule, gene-modified cell therapy, oligonucleotide, peptide, protein, and synthetic peptide.
-
What are the key companies in the encephalomyelitis pipeline market?
The key companies in the encephalomyelitis pipeline market are AIM ImmunoTech Inc, Biovista Inc, Cortene Inc, F. Hoffmann-La Roche Ltd, K-Pax Pharmaceuticals Inc, NLS Pharmaceutics AG, Orion BioScience Inc, Paxmedica Inc, Telesphore Pharma, Trethera Corp, and Virios Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.